Table 1

Patient characteristics

No. (%)
Age median (range)58 (30–88)
Gender
 Male42 (46)
 Female50 (54)
Type of cancer
 Melanoma80 (87)
 NSCLC12 (13)
Immunotherapy among 96 episodes
 Ipilimumab (3 mg/kg)44 (46)
 Ipilimumab (10 mg/kg)10 (10)
 Nivolumab11 (12)
 Pembrolizumab10 (10)
 Sequential ipilimumab+pembrolizumab7 (7)
 Sequential ipilimumab+nivolumab2 (2)
 Combined ipilimumab+nivolumab12 (13)
Diarrhoea at presentation among 96 episodes
 Grade 115 (16)
 Grade 237 (39)
 Grade 343 (44)
 Grades 4–50 (0)
 Unknown1 (1)
Prednisone at start of diarrhoea
 None4 (4)
 <1 mg/kg32 (33)
 1 mg/kg57 (60)
 >1 mg/kg3 (3)
Budesonide
 No84 (87)
 Yes12 (13)
Infliximab
 No42 (44)
 Yes54 (56)
Mycophenolic acid
 No93 (97)
 Yes3 (3)
Tacrolimus
 No94 (98)
 Yes2 (2)
  • NSCLC, non-small cell lung cancer.